ALNY vs. TAK: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at ALNY and TAK, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Overview
ALNY’s market capitalization stands at 43.28 billion USD, while TAK’s is 48.28 billion USD, indicating their market valuations are broadly comparable.
With betas of 0.21 for ALNY and 0.26 for TAK, both stocks show similar sensitivity to overall market movements.
TAK is an American Depositary Receipt (ADR), allowing U.S. investors direct exposure to its non-U.S. operations. ALNY, on the other hand, is a domestic entity.
| Symbol | ALNY | TAK |
|---|---|---|
| Company Name | Alnylam Pharmaceuticals, Inc. | Takeda Pharmaceutical Company Limited |
| Country | US | JP |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Drug Manufacturers - Specialty & Generic |
| CEO | Yvonne L. Greenstreet | Christophe Weber |
| Price | 331.91 USD | 15.34 USD |
| Market Cap | 43.28 billion USD | 48.28 billion USD |
| Beta | 0.21 | 0.26 |
| Exchange | NASDAQ | NYSE |
| IPO Date | June 1, 2004 | January 5, 2010 |
| ADR | No | Yes |
Historical Performance
This chart compares the performance of ALNY and TAK by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period.
Data is adjusted for dividends and splits.
Profitability
Return on Equity
ALNY
-509.33%
Biotechnology Industry
- Max
- 72.39%
- Q3
- -6.30%
- Median
- -32.82%
- Q1
- -68.26%
- Min
- -147.61%
ALNY has a negative Return on Equity of -509.33%. This indicates the company is generating a loss for its shareholders, which can be a result of unprofitability or negative shareholder equity and is often a sign of financial distress.
TAK
1.48%
Drug Manufacturers - Specialty & Generic Industry
- Max
- 51.32%
- Q3
- 9.89%
- Median
- -3.37%
- Q1
- -20.99%
- Min
- -36.07%
TAK’s Return on Equity of 1.48% is on par with the norm for the Drug Manufacturers - Specialty & Generic industry, indicating its profitability relative to shareholder equity is typical for the sector.
Return on Invested Capital
ALNY
-2.79%
Biotechnology Industry
- Max
- 48.74%
- Q3
- -10.68%
- Median
- -31.65%
- Q1
- -52.92%
- Min
- -113.69%
ALNY has a negative Return on Invested Capital of -2.79%. This indicates that its operations are failing to generate a profit on the total capital invested, signaling significant inefficiency or value destruction.
TAK
2.23%
Drug Manufacturers - Specialty & Generic Industry
- Max
- 22.54%
- Q3
- 8.45%
- Median
- 1.42%
- Q1
- -9.01%
- Min
- -28.41%
TAK’s Return on Invested Capital of 2.23% is in line with the norm for the Drug Manufacturers - Specialty & Generic industry, reflecting a standard level of efficiency in generating profits from its capital base.
Net Profit Margin
ALNY
-11.49%
Biotechnology Industry
- Max
- 87.75%
- Q3
- -5.05%
- Median
- -103.44%
- Q1
- -1,032.77%
- Min
- -2,366.07%
ALNY has a negative Net Profit Margin of -11.49%, indicating the company is operating at a net loss as its expenses exceeded its revenues.
TAK
2.36%
Drug Manufacturers - Specialty & Generic Industry
- Max
- 40.33%
- Q3
- 11.92%
- Median
- -0.45%
- Q1
- -13.07%
- Min
- -34.27%
TAK’s Net Profit Margin of 2.36% is aligned with the median group of its peers in the Drug Manufacturers - Specialty & Generic industry. This indicates its ability to convert revenue into profit is typical for the sector.
Operating Profit Margin
ALNY
-4.91%
Biotechnology Industry
- Max
- 87.75%
- Q3
- -3.28%
- Median
- -115.26%
- Q1
- -1,188.86%
- Min
- -2,943.30%
ALNY has a negative Operating Profit Margin of -4.91%. This signifies the company is unprofitable at the operational level, as its core business expenses exceed its revenue.
TAK
9.62%
Drug Manufacturers - Specialty & Generic Industry
- Max
- 46.91%
- Q3
- 19.02%
- Median
- 6.23%
- Q1
- -11.23%
- Min
- -51.89%
TAK’s Operating Profit Margin of 9.62% is around the midpoint for the Drug Manufacturers - Specialty & Generic industry, indicating that its efficiency in managing core business operations is typical for the sector.
Profitability at a Glance
| Symbol | ALNY | TAK |
|---|---|---|
| Return on Equity (TTM) | -509.33% | 1.48% |
| Return on Assets (TTM) | -6.40% | 0.76% |
| Return on Invested Capital (TTM) | -2.79% | 2.23% |
| Net Profit Margin (TTM) | -11.49% | 2.36% |
| Operating Profit Margin (TTM) | -4.91% | 9.62% |
| Gross Profit Margin (TTM) | 86.01% | 54.70% |
Financial Strength
Current Ratio
ALNY
3.04
Biotechnology Industry
- Max
- 28.73
- Q3
- 13.97
- Median
- 6.31
- Q1
- 3.60
- Min
- 0.02
ALNY’s Current Ratio of 3.04 falls into the lower quartile for the Biotechnology industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.
TAK
1.01
Drug Manufacturers - Specialty & Generic Industry
- Max
- 5.74
- Q3
- 3.37
- Median
- 2.64
- Q1
- 1.73
- Min
- 0.88
TAK’s Current Ratio of 1.01 falls into the lower quartile for the Drug Manufacturers - Specialty & Generic industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.
Debt-to-Equity Ratio
ALNY
11.28
Biotechnology Industry
- Max
- 0.46
- Q3
- 0.22
- Median
- 0.06
- Q1
- 0.02
- Min
- 0.00
With a Debt-to-Equity Ratio of 11.28, ALNY operates with exceptionally high leverage compared to the Biotechnology industry norm. This suggests an aggressive reliance on debt financing, which can magnify returns but also significantly elevates financial risk.
TAK
0.65
Drug Manufacturers - Specialty & Generic Industry
- Max
- 1.45
- Q3
- 1.06
- Median
- 0.62
- Q1
- 0.13
- Min
- 0.00
TAK’s Debt-to-Equity Ratio of 0.65 is typical for the Drug Manufacturers - Specialty & Generic industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
Interest Coverage Ratio
ALNY
-0.79
Biotechnology Industry
- Max
- 108.32
- Q3
- -0.55
- Median
- -8.49
- Q1
- -74.83
- Min
- -168.36
ALNY has a negative Interest Coverage Ratio of -0.79. This indicates that its earnings were insufficient to cover even its operational costs, let alone its interest payments, signaling significant financial distress.
TAK
2.10
Drug Manufacturers - Specialty & Generic Industry
- Max
- 10.17
- Q3
- 3.39
- Median
- 0.85
- Q1
- -2.63
- Min
- -5.84
TAK’s Interest Coverage Ratio of 2.10 is positioned comfortably within the norm for the Drug Manufacturers - Specialty & Generic industry, indicating a standard and healthy capacity to cover its interest payments.
Financial Strength at a Glance
| Symbol | ALNY | TAK |
|---|---|---|
| Current Ratio (TTM) | 3.04 | 1.01 |
| Quick Ratio (TTM) | 2.98 | 0.52 |
| Debt-to-Equity Ratio (TTM) | 11.28 | 0.65 |
| Debt-to-Asset Ratio (TTM) | 0.31 | 0.32 |
| Net Debt-to-EBITDA Ratio (TTM) | -1.85 | 3.57 |
| Interest Coverage Ratio (TTM) | -0.79 | 2.10 |
Growth
The following charts compare key year-over-year (YoY) growth metrics for ALNY and TAK. These metrics are based on the companies’ annual financial reports.
Revenue Growth
Earnings Per Share (EPS) Growth
Free Cash Flow Growth
Dividend
Dividend Yield
ALNY
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
ALNY currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
TAK
4.41%
Drug Manufacturers - Specialty & Generic Industry
- Max
- 9.29%
- Q3
- 0.31%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
With a Dividend Yield of 4.41%, TAK offers a more attractive income stream than most of its peers in the Drug Manufacturers - Specialty & Generic industry, signaling a strong commitment to shareholder returns.
Dividend Payout Ratio
ALNY
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
ALNY has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
TAK
280.28%
Drug Manufacturers - Specialty & Generic Industry
- Max
- 125.42%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
TAK’s Dividend Payout Ratio of 280.28% is above 100%. This means the company is paying out more in dividends than it earned, a practice that is often unsustainable and could indicate a risk to future dividend stability.
Dividend at a Glance
| Symbol | ALNY | TAK |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 4.41% |
| Dividend Payout Ratio (TTM) | 0.00% | 280.28% |
Valuation
Price-to-Earnings Ratio
ALNY
-159.59
Biotechnology Industry
- Max
- 78.44
- Q3
- 48.98
- Median
- 20.50
- Q1
- 12.64
- Min
- 2.14
ALNY has a negative P/E Ratio of -159.59. This occurs when a company has negative earnings (a net loss), making the ratio unsuitable for valuation analysis.
TAK
65.07
Drug Manufacturers - Specialty & Generic Industry
- Max
- 40.89
- Q3
- 28.12
- Median
- 23.94
- Q1
- 18.79
- Min
- 7.76
At 65.07, TAK’s P/E Ratio is exceptionally high, exceeding the typical maximum for the Drug Manufacturers - Specialty & Generic industry. This suggests the stock may be significantly overvalued compared to its peers and implies high market expectations that could be difficult to meet.
Forward P/E to Growth Ratio
ALNY
-43.29
Biotechnology Industry
- Max
- 2.29
- Q3
- 1.10
- Median
- 0.49
- Q1
- 0.16
- Min
- 0.02
ALNY has a negative Forward PEG Ratio of -43.29. This typically results from negative earnings or forecasts of declining future earnings, making the ratio not meaningful for valuation.
TAK
3.23
Drug Manufacturers - Specialty & Generic Industry
- Max
- 4.19
- Q3
- 2.94
- Median
- 1.47
- Q1
- 0.35
- Min
- 0.00
A Forward PEG Ratio of 3.23 places TAK in the upper quartile for the Drug Manufacturers - Specialty & Generic industry. This suggests the stock is potentially expensive compared to its peers relative to its growth forecast, which may warrant caution.
Price-to-Sales Ratio
ALNY
18.43
Biotechnology Industry
- Max
- 110.90
- Q3
- 59.76
- Median
- 11.33
- Q1
- 4.45
- Min
- 0.17
ALNY’s P/S Ratio of 18.43 aligns with the market consensus for the Biotechnology industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
TAK
1.53
Drug Manufacturers - Specialty & Generic Industry
- Max
- 7.49
- Q3
- 4.45
- Median
- 2.12
- Q1
- 1.21
- Min
- 0.25
TAK’s P/S Ratio of 1.53 aligns with the market consensus for the Drug Manufacturers - Specialty & Generic industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
Price-to-Book Ratio
ALNY
372.86
Biotechnology Industry
- Max
- 15.78
- Q3
- 7.44
- Median
- 3.31
- Q1
- 1.58
- Min
- 0.31
The P/B Ratio is often not a primary valuation metric for the Biotechnology industry.
TAK
1.01
Drug Manufacturers - Specialty & Generic Industry
- Max
- 4.93
- Q3
- 3.95
- Median
- 2.14
- Q1
- 1.30
- Min
- 0.13
The P/B Ratio is often not a primary valuation metric for the Drug Manufacturers - Specialty & Generic industry.
Valuation at a Glance
| Symbol | ALNY | TAK |
|---|---|---|
| Price-to-Earnings Ratio (P/E, TTM) | -159.59 | 65.07 |
| Forward PEG Ratio (TTM) | -43.29 | 3.23 |
| Price-to-Sales Ratio (P/S, TTM) | 18.43 | 1.53 |
| Price-to-Book Ratio (P/B, TTM) | 372.86 | 1.01 |
| Price-to-Free Cash Flow Ratio (P/FCF, TTM) | -574.08 | 9.97 |
| EV-to-EBITDA (TTM) | -285.32 | 9.61 |
| EV-to-Sales (TTM) | 18.55 | 2.43 |